← Back to Clinical Trials
Recruiting NCT06181149

NCT06181149 Auditory Prediction and Error Evaluation in the Speech of Individuals Who Stutter

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06181149
Status Recruiting
Phase
Sponsor Arizona State University
Condition Healthy Subjects
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2024-01-01
Primary Completion 2027-12-30

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Delaying speech initiationAuditory errors and pre-speech auditory modulationContributions of the speech premotor cortex to pre-speech auditory modulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2024-01-01 with a primary completion date of 2027-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Stuttering negatively impacts communication and reduces the overall quality of life and well-being of individuals who stutter. This study will provide a strong foundation for developing neural and behavioral interventions for stuttering. Participants will be asked to name pictures, read words/sentences silently or aloud, and listen to speech and nonspeech sounds while their speech, muscle, and brain signals are collected. Some participants may also receive brain stimulation while reading and speaking.

Eligibility Criteria

Inclusion Criteria: * being a monolingual, native speaker of American English * absence of developmental, psychological, neurological, or communication disorders (other than developmental stuttering) as confirmed by a certified research SLP * normal (age-appropriate) binaural pure-tone hearing threshold (0.5-4k Hz; ≤25 dB HL for younger than 70 years, and ≤35 dB HL for older than 70 years) * not taking any medications that affect the central nervous system * absence of safety contra-indication for tDCS, TMS and MRI (for adults) * scoring at the 20th percentile or higher on standardized speech-language tests (for children) Exclusion Criteria: \-

Contact & Investigator

Central Contact

Ayoub Daliri, PhD

✉ ayoub.daliri@asu.edu

📞 4807278397

Frequently Asked Questions

Who can join the NCT06181149 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, studying Healthy Subjects. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06181149 currently recruiting?

Yes, NCT06181149 is actively recruiting participants. Contact the research team at ayoub.daliri@asu.edu for enrollment information.

Where is the NCT06181149 trial being conducted?

This trial is being conducted at Tempe, United States, Seattle, United States.

Who is sponsoring the NCT06181149 clinical trial?

NCT06181149 is sponsored by Arizona State University. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology